Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)


OwnershipChart

Previous Close

$0.08

52W Range

$0.06 - $1.31

50D Avg

$0.11

200D Avg

$0.26

Market Cap

$778.33K

Avg Vol (3M)

$28.58K

Beta

1.38

Div Yield

-

BLCM Company Profile


Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Dec 18, 2014

Website

BLCM Performance


Latest Earnings Call Transcripts


Q4 20Mar 30, 21 | 10:23 PM
Q2 20Aug 07, 20 | 5:00 PM
Q4 19Mar 13, 20 | 5:00 PM

Peer Comparison


TickerCompany
CALACalithera Biosciences, Inc.
ATRAAtara Biotherapeutics, Inc.
CLLSCellectis S.A.
ADAPAdaptimmune Therapeutics plc
AFMDAffimed N.V.